Paclitaxel With or Without Napabucasin in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized, double-blind, placebo-controlled phase 3 study of paclitaxel {plus minus} napabucasin in pretreated advanced gastric or gastroesophageal junction adenocarcinoma
Clin. Cancer Res 2022 May 26;[EPub Ahead of Print], MA Shah, K Shitara, F Lordick, YJ Bang, NC Tebbutt, JP Metges, K Muro, KW Lee, L Shen, S Tjulandin, JL Hays, N Starling, RH Xu, K Sturtz, M Fontaine, C Oh, E Brooks, B Xu, W Li, CJ Li, L Borodyansky, E Van CutsemFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.